As described above, there is a substantial body of literature detailing the role of cGAS/STING and other TLRs in the regulating the anti-tumor response to DNA-damaging therapies primarily through control of the adaptive immune response ultimately leading to CD8+ T-cell-mediated tumor cell death [68,87]. The gene discussed is CGAS; the disease is neoplasm.